In a separate announcement, Praxis revealed it successfully completed a pre-NDA meeting with the FDA regarding ulixacaltamide, its treatment for essential tremor. The company has gained alignment from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback